4Vote!
Business Wire (Free subscription) | yesterday
ROCKVILLE, Md. & MONTREAL--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) and Aegera Therapeutics, Inc. today announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors. “We are pleased to initiate this first human study of HGS1029 in lymphoid...
4Vote!
bizjournals (Free subscription) | 11/16/2009
Human Genome Sciences Inc. said federal regulators still need more information before they can approve the Rockville company’s anthrax treatment, delivering a blow in what’s otherwise been a good month for the company. (HGSI)
4Vote!
Fiercebiotech (Free subscription) | 11/16/2009
Human Genome Sciences ( HGSI ) says the FDA has denied its bid to gain an approval for its anthrax drug, asking for additional information on raxibacumab in a complete response letter. The delay is not a big surprise, given the recent vote by an advisory council to request more data on what benefits the drug provides beyond antibiotics. And the news hardly dented HGS stock in premarket trading; the...
4Vote!
Business Wire (Free subscription) | 11/16/2009
ROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) relating to the Company’s Biologics License Application (BLA) requesting the approval of raxibacumab for use in the treatment of inhalational anthrax. The FDA issues Complete Response Letters to request additional...
5Vote!
SeekingAlpha.com (Free subscription) | 11/05/2009
Zacks.com submits: Human Genome Sciences, Inc. ( HGSI ) reported third quarter net loss of $49 million or 32 cents per share, in-line with the Zacks Consensus Estimate. The company reported a net loss of $74.2 million or 50 cents in the year ago quarter. The lower net loss for the quarter was primarily attributable to increased revenues from manufacturing and development services and lower operating...
5Vote!
Jim Cramer's Mad Money (Free subscription) | 11/05/2009
Jim Cramer’s Mad Money Stock Picks for Wednesday November 4 2009. These are all of Jim Cramer’s stock picks that are a Buy! I bold my picks. Buy: Tessera Technologies (TSRA) EnCana (ECA) Wendy’s/Arby’s Group (WEN) Wellpoint (WLP) Immunogen (IMGN) Human Genome Sciences (HGSI) Goldman Sachs (GS) Sims Group (SMS) Sell: Seattle Genetics (SGEN) Always do your own research as these...
5Vote!
Volume Spike Investor (Free subscription) | 11/03/2009
Human Genome Sciences Inc. (NASDAQ: HGSI) was lower this morning and had been off our radar as a result after yesterday’s huge moves. Yet at 1:30 PM EST we have just hit the virtual double on average daily volume. Shares are up 8% at $27.34 on about 16.2 million shares versus and average volume of [...]
5Vote!
SeekingAlpha.com (Free subscription) | 11/02/2009
Ockham Research submits: For all the debate about possible reform to the U.S. medical system, it is easy to forget that the majority of major innovations in drugs and medical devices come from America. It is worth remembering that even with all the problems troubling the health care system, innovation continues to be a bright spot. Three of the biggest gains among individual stocks on Monday were...
11Vote!
The Business Insider (Free subscription) | 11/02/2009
Today the market started on the upswing, renewing investor confidence after last week's drubbing. Almost. Hours later the major indexes were swinging back and forth like gauntlet. In the end, the Dow squeezed out a 76 point gain while the S&P500 and NASDAQ gained 7 points and 3 points, respectively. Ford (F) was undoubtedly the star of the show , posting a nearly $1 billion profit which sent shares...
4Vote!
MarketIntelligenceCenter.com (Free subscription) | 11/02/2009
Human Genome Sciences (NGM: HGSI) hit a new 52-Week high of $26.21 so far today. Currently the stock is up $5.21 (27.88%) to $23.90 on 34,868,684 shares traded. Today's high is up $23.45 from a 52-Week Low of $0.45. HGSI reported positive results on its experimental lupus drug. Human Genome Sciences stock has been showing support around $17.56 and resista...
5Vote!
SeekingAlpha.com (Free subscription) | 11/02/2009
EP Vantage submits: The high hopes that both the market and sufferers from lupus hold for Human Genome Sciences' ( HGSI ) lead drug, Benlysta, showed no signs of being dashed Monday after the group and partner GlaxoSmithKline ( GSK ) released the hotly awaited 52-week data from their Bliss-76 trial. While the data was not as strong as the original Bliss-52 trial, it still leaves Benlysta as the only...
5Vote!
CEOWORLD Magazine (Free subscription) | 11/02/2009
Human Genome Sciences (NASDAQ:HGSI) and GlaxoSmithKline PLC (NYSE:GSK) announced Monday morning that BENLYSTA met the primary endpoint in the second of two Phase 3 trials in seropositive patients with systemic lupus erythematosus. Companies hope will be the first treatment to receive approval for lupus in over 50 years. The drug works by suppressing the immune system’s response to lupus, and...
4Vote!
Stock Market Analysis (Free subscription) | 11/02/2009
Today, November 2, 2009, there are several stock gainers that are breaking out with some nice momentum. If you are looking to day trade today, you might want to check out the following stocks. Check out some of today's biggest gainers and the Top Stocks for 2009 . You can find my Past, Current, and Future Stock Gainers Report Right Here Top Stocks 11/2/09 - Biggest Gainers Today Discuss Stocks - www.stockstobuy.org...
Videos